Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Brief Potent Glutamatergic Modulation on Cocaine Dependence

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Active cocaine dependence with at least 8 days of use or at least 4 binges of large amounts (\>$200/occasion) over the past 30 days, and displaying at least one positive utox during screening~* Physically healthy~* No adverse reactions to study medications~* 21-60 years of age~* Capacity to consent and comply with study procedures, including sufficient proficiency in English~* Seeking treatment~Exclusion Criteria:~* Meets DSM IV criteria for current major depression, bipolar disorder, schizophrenia, any psychotic illness, including substance induced psychosis, and current substance-induced mood disorder with HAMD score \> 12.~* Physiological dependence on another substance requiring medical management, such as alcohol, opioids, or benzodiazepines, excluding caffeine, nicotine, and cannabis~* Delirium, Dementia, Amnesia, Cognitive Disorders, or Dissociative disorders~* Current suicide risk or a history of suicide attempt within the past year~* Pregnant or interested in becoming pregnant during the study period~* Heart disease as indicated by history, abnormal ECG, previous cardiac surgery.~* Unstable physical disorders which might make participation hazardous such as end-stage AIDS, hypertension (\>140/90), WBC \< 3.5, active hepatitis or other liver disease with elevated transaminase levels (\< 2-3 X upper limit of normal will be considered acceptable if PT/PTT is normal), renal failure (creatinine \> 2, BUN \>40), or untreated diabetes~* Previous history of ketamine or benzodiazepine misuse or abuse, and a history of an adverse reaction/experience with prior exposure to ketamine or benzodiazepine~* Recent history of significant violence (past 2 years)~* First degree relative with a psychotic disorder (bipolar disorder, schizophrenia, schizoaffective disorder, or psychosis NOS)~* BMI \> 32, or a history of documented obstructive sleep apnea~* On psychotropic or other medications whose effect could be disrupted by participation in the study~* Patients who cannot comply with study procedures during the initial hospitalization phase

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Ketamine (Type: EXPERIMENTAL): 0.5 mg/kg of ketamine IV over 40 minutes
- midazolam (Type: ACTIVE_COMPARATOR): 0.025 mg/kg IV over 40 minutes

Based on this trial design, predict the completion outcome and termination type (if applicable).